| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President
1 company
Srdjan R. Stankovic last filed a Form 4 in November 2022, as President at ACAD. Srdjan R. Stankovic's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Srdjan R. Stankovic's trades have earned a middling insider score of 62/100 across 9 rated trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of +3.5%.
At the last filing, the largest reported position was 61,234 shares of ACAD. The ACAD filings lean toward selling, a net 386,840 shares.
Srdjan R. Stankovic has 30 Form 4 filings on record from November 2015 to November 2022, all as President at Acadia Pharmaceuticals (ACAD), 2015–2022.
The 73 reported transactions were 28 option exercises, 23 open-market sales, 21 option or other derivative awards and 1 stock award.
Counted by filing, the open-market trades come to no purchases and 19 sales worth about $19.3M.
The largest open-market sale was 154,019 shares of ACAD at an average $50.11 on April 22, 2020, about $7.7M.
Shares as reported in the last Form 4 for each company; the most recent is from November 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 21, 2022 | ACAD Acadia Pharmaceuticals Inc | President | Sale+OE | 1,847 | $15.07 | $27,834.29 | -2.9% | +26.0% | +51.9% | |
| Oct 15, 2022 | ACAD Acadia Pharmaceuticals Inc | President | Sale+OE | 1,326 | $15.81 | $20,964.06 | -2.3% | +17.0% | +51.3% | |
| May 2, 2022 | ACAD Acadia Pharmaceuticals Inc | President | Sale+OE | 2,865 | $18.18 | $52,090.86 | -4.9% | -27.8% | +9.4% | |
| Feb 23, 2022 | ACAD Acadia Pharmaceuticals Inc | President | Sale+OE | 1,501 | $23.80 | $35,723.80 | -3.0% | -35.3% | -22.6% | |
| Jan 6, 2022 | ACAD Acadia Pharmaceuticals Inc | President | Sale+OE | 1,937 | $23.05 | $44,647.85 | -4.1% | +16.4% | -26.0% | |
| Nov 22, 2021 | ACAD Acadia Pharmaceuticals Inc | President | Sale+OE | 2,803 | $19.01 | $53,285.03 | -6.3% | +35.6% | -22.0% | |
| Oct 18, 2021 | ACAD Acadia Pharmaceuticals Inc | President | Sale+OE | 1,338 | $17.41 | $23,294.58 | -3.4% | +19.0% | -8.9% | |
| Apr 30, 2021 | ACAD Acadia Pharmaceuticals Inc | President | Sale+OE | 4,230 | $20.33 | $85,995.90 | -10.4% | +8.4% | -10.3% | |
| Feb 4, 2021 | ACAD Acadia Pharmaceuticals Inc | President | Sell | 8,429 | $50.61 | $426,591.69 | -21.4% | -62.2% | -54.0% | |
| Jan 12, 2021 | ACAD Acadia Pharmaceuticals Inc | President | Sale+OE | 700 | $55.01 | $38,507.00 | -3.3% | - | - |